Clinical trials: Alopecia Totalis/Universalis
Recalcitrant Alopecia Totalis, Recalcitrant Alopecia Universalis
The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis
The main purpose of this study is to determine the efficacy of intralesional botulinum toxin type A injection for recalcitrant alopecia totalis and alopecia universalis.
- Trial name
- NCT00997815
- Testing
- Botulinum toxin A, Normal saline injection
- Where
- Thailand
- Volunteers
- 20 people
- Sponsor
- Siriraj Hospital
Alopecia Universalis (AU), Alopecia Totalis (AT)
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
The primary objective is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution compared to vehicle in subjects with AU and AT.
- Trial name
- NCT03315689
- Testing
- Vehicle, ATI-50002
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia Areata, Alopecia Universalis
ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)
This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: To assess the safety, tolerability, and efficacy of ATI-502 Topical Solution in subjects with AA, AU or AT…
- Conditions
- Alopecia Areata, Alopecia Universalis, Alopecia Totalis
- Trial name
- NCT03759340
- Testing
- ATI 502 0.46% Topical Solution
- Where
- 20 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia Areata
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata.
- Trial name
- ALLEGRO-100 (NCT06873945)
- Testing
- Ritlecitinib 100 mg, Ritlecitinib 50 mg
- Where
- 148 sites in United States, Canada and 9 more
- Volunteers
- 674 people
- Sponsor
- Pfizer
Alopecia Areata, Alopecia Totalis
Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
Alopecia Areata (AA) is among the most highly prevalent human autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the hair follicle and subsequent autoimmune attack.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT06747611
- Testing
- Vancomycin, Neomycin and MTT capsules
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Alopecia
A Randomised Control Trial of Integrative Cognitive Behavioural Therapy for Alopecia
This Randomised Control Trial (RCT) aims to test a novel Alopecia-tailored, protocolled, integrative individual psychological intervention offered to patients with enduring Alopecia.
- Trial name
- NCT04205214
- Testing
- Integrative Cognitive Behavioural Therapy
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- City, University of London
Alopecia Areata
Long-Term PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata.
- Trial name
- ALLEGRO-LT (NCT04006457)
- Testing
- PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 1,057 people
- Sponsor
- Pfizer
Alopecia Areata
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.
- Trial name
- NCT02553330
- Testing
- Ruxolitinib Phosphate Cream
- Where
- 18 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Alopecia Areata, Alopecia Totalis
Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata
The purpose of this study is to examine fecal transfer as a potential treatment for Alopecia Areata (AA). This trial will attempt to discover if fecal transfer can treat immune-related hair loss.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT04238091
- Testing
- Fecal material transfer therapy, 4mm Punch Biopsy of Scalp, Blood draw
- Sponsor
- Lindsey Bordone
Alopecia Areata
Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata
The goal of this clinical research study is to find the most effective dose of Targretin® (bexarotene) Gel 1% that can be given to patients as a treatment for alopecia areata.
- Trial name
- NCT00063076
- Testing
- Targretin Gel 1%
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Alopecia Totalis/Universalis, Alopecia Areata(AA)
Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation
The goal of this observational study is to evaluate safety of Rhofanib® (Tofacitinib) in male or female participants with the age of 18 years or older having clinical diagnosis of Alopecia.
- Trial name
- NCT07101471
- Testing
- Tofacitinib
- Where
- Iran
- Volunteers
- 296 people
- Sponsor
- NanoAlvand
Alopecia Totalis, Alopecia Universalis
Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata
Systemic Pulse Glucocorticoids have been shown to be effective in widespread Alopecia areata but not the totalis, universalis or ophiasic type.
- Conditions
- Alopecia Totalis, Alopecia Universalis, Ophiasic Alopecia
- Trial name
- NCT01167946
- Testing
- methylprednisolone sodium succinate
- Where
- Saudi Arabia
- Volunteers
- 42 people
- Sponsor
- King Saud University
Alopecia Areata, Alopecia
Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
The purpose of this study is to assess the safety, PK, and PD of EQ101 as well as measure the efficacy of EQ101 at Week 24 compared to Baseline in adult subjects with moderate to severe AA.
- Conditions
- Alopecia Areata, Alopecia, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT05589610
- Testing
- EQ101
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 36 people
- Sponsor
- Equillium
Alopecia Areata, Alopecia Totalis
Tofacitinib for the Treatment of Alopecia Areata and Its Variants
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT02312882
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Alopecia
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
This Phase 2, multicenter, randomized study will evaluate the safety, tolerability and efficacy of ATI-501 for the treatment of Alopecia Areata (AA), Alopecia Universalis (AU) or Alopecia Totalis (AT) in adult subjects.
- Trial name
- NCT03594227
- Testing
- ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose)
- Where
- 25 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia Areata, Alopecia Totalis
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
The study series consists of three studies with the aim to assess the incidence, prevalence, risk factors, comorbidities and management of patients with alopecia areata in Czech Republic based on the patients and registry of a…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Alopecia Areata (& Ophiasis)
- Trial name
- NCT05098600
- Testing
- Exposure of interest
- Where
- Czechia
- Volunteers
- 123 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Alopecia Areata, Alopecia Totalis
Alopecia Areata Registry
Alopecia areata is the loss of hair in patches that can proceed to loss of all hair (alopecia totalis or universalis). The purpose of the registry is to collect patient information and blood samples from people with alopecia…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Autoimmune Hair Loss
- Trial name
- NAAR (NCT00069589)
- Where
- 5 sites in United States
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Alopecia Totalis
Efalizumab in the Treatment of Alopecia, Phase II
Determine the effect that treatment with efalizumab has on scalp hair re-growth in younger adults affected by severe variants of alopecia areata, including alopecia totalis, alopecia universalis, and severe ophiasis variants.
- Trial name
- NCT00746980
- Testing
- efalizumab
- Sponsor
- Northwestern University
Alopecia Areata (AA), Alopecia Totalis (AT)
Tofacitnib for the Treatment of Alopecia Areata and Variants
The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.
- Conditions
- Alopecia Areata (AA), Alopecia Totalis (AT), Alopecia Universalis (AU)
- Trial name
- NCT02197455
- Testing
- Tofacitinib Administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Alopecia Areata
Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata
The objective of this study is to assess the safety and efficacy of Tofacitinib in treating patients with extensive and recalcitrant Alopecia Areata (AA), along with to evaluate the economic impact of the patients that may be…
- Trial name
- NCT03800979
- Testing
- Tofacitinib
- Where
- Thailand
- Volunteers
- 19 people
- Sponsor
- Institute of Dermatology, Thailand